Methylgene Inc. (fka MYLGF)

[Renee]

MYLGF: Plan of Arrangement; Shareholders of MethylGene will receive one share of common stock of Mirati (a Mirati Share) for every 50 common shares of MethylGene (the MethylGene Shares) held.

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/02/2013&mkt_ctg=NON-OTCBB

[biocqr]

Montreal based Methylgene will R/S 1-50 then reincorporate in U.S. and trade on Nasdaq as Mirati Therapeutics. CEO Dr. Charles Baum is an x-Pfizer exec... headed up Pfizer oncology development and was CMO.

Quote:He was responsible for the development of the oncology portfolio, including Axitinib (Inlyta®), Crizotinib (Xalkori®) and the approval of sunitinib (Sutent®) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®) which was approved for the treatment of patients with advanced brain tumors.


http://methylgene.com/about-myg/executive-management

Lead oncology drug is MGCD265.

MGCD265 is a rationally designed, orally administered small molecule kinase inhibitor that targets the receptor tyrosine kinases (RTKs) Met, VEGFR 1,2,3 and Axl, as well as Tie2 and Ron.

Pipeline...

http://methylgene.com/pipeline-myg


METHYLGENE SHAREHOLDERS APPROVE THE PLAN OF ARRANGEMENT TO REINCORPORATE IN THE UNITED STATES AS MIRATI THERAPEUTICS INC.

Montreal, Canada, June 25, 2013 –MethylGene Inc. (“MethylGene”) (TSX:MYG) today announced that at its Annual and Special Meeting of Shareholders held in Montreal, Quebec (the “Meeting”), that over 99.99% of the votes cast by shareholders approved the previously announced plan of arrangement (the “Arrangement”), whereby, among other things, the company would migrate to the State of Delaware in the United States of America. Under the Arrangement, Mirati Therapeutics Inc. (“Mirati”), the holding company and wholly-owned subsidiary, will become the ultimate parent corporation of MethylGene and its subsidiaries, by acquiring all of the issued and outstanding common shares of MethylGene in exchange for 1 Mirati share for every 50 common shares of MethylGene.

MethylGene will apply for final approval of Arrangement by the Ontario Superior Court on June 27, 2013 and assuming receipt of court approval and satisfaction of other conditions to closing, the transaction is expected to close on or about June 28, 2013.

Concurrently with the Arrangement, Mirati is making an application to list its shares of common stock (“Mirati Shares”) on the NASDAQ Capital Market (“NASDAQ”). In connection with the NASDAQ listing, Mirati Therapeutics has filed a registration statement with the Securities and Exchange Commission in the United States on Form 10 for the purpose of registering the Mirati Shares under Section 12(g) of the Securities Exchange Act of 1934, as amended.

[crystal finishing]

Nice Day for Methylgene. More sure to come with this Real Penny play!!.... Excellent VOLUME and PRICE jump in the last two
hours of trading today.

[TenaciousD]

yup, its been flirting with a move but the market has just been to crazy as of late. They need some news/presentation/pr to bring some volume in and it will jump up quickly

glty

D

[Hedge Starz]

this sort of research and biotech subsector....IS the future. no doubt this one looks interesting considering it is one of the few publicly traded companies in this field

[TenaciousD]

interest is coming back into this, tons of potential for a small bio-pharma. Grabbed a bunch @ .20 today, will be posting any news or updates here.

GLTY

D

[TenaciousD]

UPDATE 1-MethylGene's drug to treat tumor shows promise


Thu Nov 18, 2010 11:11am EST

* Says one of the 4 NSCLC patients showed partial response * Shares up 25 pct

Nov 18 (Reuters) - Canadian drug developer MethylGene Inc (MYG.TO) said its experimental drug to treat solid tumor showed promise in a mid-stage trial, sending its shares up as much as 25 percent.

The company's drug MGCD265 is given to patients in combination with either commonly used chemotherapy drug docetaxel or non-small cell lung cancer (NSCLC) drug erlotinib.

One of the four NSCLC patients, who experienced stable disease for durations ranging from 8 to 13 months, achieved a confirmed partial response and the other three patients all had tumor shrinkage, the company said.

The company's shares were up 21 percent at 17 Canadian cents on Thursday morning on the Toronto Stock Exchange.

They had touched a high of 17.5 Canadian cents, earlier in the session. (Reporting by Isheeta Sanghi in Bangalore; Editing by Prem Udayabhanu) (([e-mail]; within U.S. [phone]; outside U.S. [phone]; Reuters Messaging: [e-mail]))

D

[TenaciousD]

entry price is a joke if this continues with good trial evaluation. Wondering if any lurkers out there holding?

D

[TenaciousD]

just got into this one, good Canadian company showing plenty of promise!

D

[Hedge Starz]

ahh......please go down to 5 cents!!!